PharmacoEconomics

Friction-Cost Method as an Alternative to the Human-Capital Approach in Calculating Indirect Costs
pp. 103-104(2)
Author: Adis International Limited

The Friction-Cost Method: Replacement for Nothing and Leisure for Free?
pp. 105-111(7)
Authors: Brouwer Werner B.F.; Koopmanschap Marc A.

The Diffusion of Health Economics Knowledge in Europe: The EURONHEED (European Network of Health Economics Evaluation Database) Project
pp. 113-120(8)
Authors: Gérard de Pouvourville; Ulmann Philippe; Nixon John; Boulenger Stéphanie; Glanville Julie; Drummond Michael

The Case for Stratified Cost-Effectiveness Analysis by Baseline Health-Related QOL: Theory and Sensitivity Analysis
pp. 121-132(12)
Author: Schaafsma Joseph

Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease
pp. 133-141(9)
Authors: Hay Joel W.; Sterling Kimberly L.

Providing Systematic Guidance in Pharmacoeconomic Guidelines for Analysing Costs
pp. 143-153(11)
Authors: Jacobs Philip; Ohinmaa Arto; Brady Bruce

Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder
pp. 155-167(13)
Authors: Fernandez José-Luis; Montgomery Stuart; Francois Clément

Cost-Minimisation Analysis of Sivelestat for Acute Lung Injury Associated with Systemic Inflammatory Response Syndrome
pp. 169-181(13)
Authors: Aikawa Naoki; Fujishima Seitaro; Kobayashi Makoto; Matsuoka Shozo; Abiru Taira

The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs
pp. 183-192(10)
Authors: Berndt Ernst; Crown William; Kallich Joel; Long Stacey; Song Xue; Lyman Gary H.

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease
pp. 193-206(14)
Authors: Plosker Greg L.; Lyseng-Williamson Katherine A.